Article
Oncology
Alan L. Ho, Irene Brana, Robert Haddad, Jessica Bauman, Keith Bible, Sjoukje Oosting, Deborah J. Wong, Myung-Ju Ahn, Valentina Boni, Caroline Even, Jerome Fayette, Maria Jose Flor, Kevin Harrington, David S. Hong, Sung-Bae Kim, Lisa Licitra, Ioanna Nixon, Nabil F. Saba, Stephan Hackenberg, Pol Specenier, Francis Worden, Binaifer Balsara, Mollie Leoni, Bridget Martell, Catherine Scholz, Antonio Gualberto
Summary: This study evaluated the efficacy of Tipifarnib in patients with HRAS mutations in R/M HNSCC, showing an objective response rate of 55% in high-VAF HNSCC patients. Tipifarnib demonstrated longer progression-free survival and overall survival compared to previous therapies, with the most frequent treatment-emergent adverse events being anemia and lymphopenia.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Zijing Liu, Zhuangzhuang Zheng, Lihua Dong, Xiao Guo, Xiaojing Jia, Jianfeng Wang, Lingbin Meng, Xiangyan Cui, Xin Jiang
Summary: Apatinib showed good efficacy and mild adverse effects in the treatment of patients with recurrence or metastasis inoperable head and neck squamous cell carcinoma. It can be considered as a second-line or above-line treatment option for these patients.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Patrick Pauwels, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters
Summary: The study identifies increased Akt1/2/3 phosphorylation as a characteristic of acquired cetuximab resistance in HNSCC cell lines. The research also demonstrates an additive to synergistic interaction between cetuximab and MK2206 in simultaneous treatment schedules. These findings suggest that combining cetuximab with PI3K/Akt pathway inhibition could be a promising novel therapeutic strategy for overcoming acquired cetuximab resistance in HNSCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Review
Biochemistry & Molecular Biology
Naoya Kitamura, Shinya Sento, Yasumasa Yoshizawa, Eri Sasabe, Yasusei Kudo, Tetsuya Yamamoto
Summary: In recent years, drug therapy for head and neck squamous cell carcinoma (HNSCC) has made rapid progress, with a focus on molecular targeted therapy and immune checkpoint inhibitors in addition to traditional cytotoxic anti-cancer agents. While the importance of anti-cancer drug therapy continues to increase, current trends and future prospects of molecular targeted therapy in HNSCC are being explored in clinical trials.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Anna Lee, Robbie Woods, Amgad Mahfouz, Sarin Kitpanit, Olivia Cartano, Nader Mohamed, Irini Youssef, Kathryn Marqueen, Kevin Sine, Dennis Mah, Brian Neal, Kaveh Zakeri, Jung J. Kang, Nadeem Riaz, Yao Yu, Sean M. McBride, Linda D. Chen, C. Jillian Tsai, Daphna Y. Gelblum, Robert H. Press, Loren S. Michel, Eric J. Sherman, David Pfister, Lara A. Dunn, Alan L. Ho, James Fetten, Richard J. Wong, Jay O. Boyle, Bhuvanesh Singh, Jennifer R. Cracchiolo, Ian Ganly, Marc A. Cohen, Nancy Y. Lee
Summary: This retrospective cohort study evaluated the outcomes and toxic effects of proton therapy reirradiation (PT-ReRT) in patients with head and neck squamous cell carcinoma. The study found that PT-ReRT can improve survival rates, but patients are still at risk of early and late complications.
Article
Biochemistry & Molecular Biology
Kento Okamoto, Toshinori Ando, Hiroki Izumi, Susumu S. Kobayashi, Tomoaki Shintani, J. Silvio Gutkind, Souichi Yanamoto, Mutsumi Miyauchi, Mikihito Kajiya
Summary: The Hippo signaling pathway and its downstream effector YAP play a central role in cell proliferation. Dysregulation of the Hippo pathway triggers YAP hyperactivation, thereby inducing head and neck squamous cell carcinoma (HNSCC). Our findings suggest that co-targeting both AXL and EGFR represent a promising therapeutic approach in patients with EGFR-altered cancers.
Review
Biochemistry & Molecular Biology
Soma Ghosh, Pooja A. Shah, Faye M. Johnson
Summary: Head and neck squamous cell carcinomas (HNSCCs) are common cancers that often recur and metastasize. Tobacco and alcohol use are associated with HNSCCs in the oral cavity and larynx, while HPV infection, particularly HPV16, is increasingly recognized as a cause of oropharyngeal HNSCC. Current treatment approaches have similar strategies for both HPV-positive and HPV-negative HNSCCs, but carry a high risk of toxic side effects. The landscape of HNSCC therapy is changing, with ongoing clinical trials investigating novel and less toxic treatment options.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Amanda E. Yung, Gareth Crouch, Alexander H. R. Varey, Serigne Lo, Michael S. Elliott, Jenny Lee, Robert Rawson, Ruta Gupta, Angela M. Hong, Jonathan R. Clark, Sydney Ch'ng
Summary: More than 60% of patients treated surgically for pT3/4 HNcSCC were alive and free of disease at 5 years posttreatment. High-risk features such as margin involvement and having had previous treatment (radiotherapy/surgery) should be used to guide adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Saba Shafi, Thazin Nwe Aung, Vasiliki Xirou, Niki Gavrielatou, Ioannis A. Vathiotis, Aileen Fernandez, Myrto Moutafi, Vesal Yaghoobi, Roy S. Herbst, Linda N. Liu, Sol Langermann, David L. Rimm
Summary: The study assesses the expression of immune system modulator Siglec-15 in different types of cancer and finds increased expression in both tumor and immune cells. The results suggest Siglec-15 as a potential target for immunotherapy and provide insights for future clinical trials and companion diagnostic tests.
LABORATORY INVESTIGATION
(2022)
Article
Oncology
Alan L. Ho
Summary: This article discusses the application of immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma, specifically the use of pembrolizumab in first-line therapy. Through a case study, the practical application of the KEYNOTE-048 study results in clinical practice is highlighted.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Ming Zhang, Ganping Wang, Zhikun Ma, Gan Xiong, Wenjin Wang, Zhengxian Huang, Yuehan Wan, Xiuyun Xu, Rosalie G. Hoyle, Chen Yi, Jinsong Hou, Xiqiang Liu, Demeng Chen, Jiong Li, Cheng Wang
Summary: This study demonstrates that BET inhibition enhances CD8+ T cell-based antitumor immunity in HNSCC by promoting the expression of MHC class I molecules. It also shows that the combination of BET inhibition with anti-PD-1 antibody treatment significantly enhances the antitumor response in HNSCC.
Article
Oncology
Brian J. Park, Austin K. Mattox, Daniel Clayburgh, Mihir Patel, R. Bryan Bell, Bevan Yueh, Rom Leidner, Hong Xiao, Marcus Couey, Shiting Li, Tingting Qin, Maureen A. Sartor, Belinda Cairns, Tracy MacDonough, Kyle Halliwill, Daniel Deschler, Derrick T. Lin, William C. Faquin, Peter M. Sadow, Sara Pai
Summary: PD-L1 testing is important for decision-making in HNSCC treatment. Chemoradiation therapy has a significant impact on PD-L1 expression, especially when using a cut-off of CPS >= 20 and >= 50. Oral cavity cancer shows higher discordance rates in local and regional recurrence, suggesting the need for repeat biopsy.
Article
Oncology
Tien-Hua Chen, Yi-Ying Pan, Tsung-Lun Lee, Ling-Wei Wang, Shyh-Kuan Tai, Pen-Yuan Chu, Wen-Liang Lo, Cheng-Hsien Wu, Muh-Hwa Yang, Peter Mu-Hsin Chang
Summary: This study investigated the treatment outcomes and clinical factors associated with better survival outcomes in patients with locally recurrent and distant metastatic squamous cell carcinoma of the head and neck who were treated with a cetuximab-containing regimen. The results showed that patients with local recurrence had longer overall survival and progression-free survival compared to those with distant metastasis, and there were more patients with oral cavity cancer and early recurrence within 6 months after radiation therapy in the local recurrence group.
Article
Oncology
Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Omid Hamid, Rubina Ismail, Igor Puzanov
Article
Pharmacology & Pharmacy
Gregory T. Gallanis, Ramon I. Pericas, Anna T. Riegel, Paula R. Pohlmann
Summary: Palbociclib shows promise in metastatic HER2+ and androgen receptor-expressing triple-negative breast cancer, with potential as an alternative to chemotherapy in the neoadjuvant setting. Ongoing research also explores the synergy of palbociclib with immunotherapies based on its effects on the tumor immune microenvironment.
EXPERT OPINION ON PHARMACOTHERAPY
(2021)
Article
Multidisciplinary Sciences
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito
Summary: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but durable response is limited. CX3CR1, a marker of T-cell differentiation, is investigated as a predictor of response to ICI therapy. Treatment with ICI increases the frequency of circulating CX3CR1(+)CD8(+) T cells and correlates with response and survival in patients with non-small cell lung cancer.
NATURE COMMUNICATIONS
(2021)
Review
Biochemistry & Molecular Biology
Jerry Xiao, Paula R. Pohlmann, Claudine Isaacs, Benjamin A. Weinberg, Aiwu R. He, Richard Schlegel, Seema Agarwal
Summary: CTCs play a crucial role in predicting patient survival and understanding the metastasis of cancer, with potential implications for disease management and treatment strategies.
Review
Oncology
Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff
Summary: This review summarizes the historical and future advances regarding the translational and clinical implications of advanced melanoma and provides multidisciplinary recommendations to aid clinicians in the navigation of current treatment approaches for a variety of patient cohorts.
JCO ONCOLOGY PRACTICE
(2022)
Review
Public, Environmental & Occupational Health
Giovana R. Onzi, Nathalia D'Agustini, Solange C. Garcia, Silvia S. Guterres, Paula R. Pohlmann, Daniela D. Rosa, Adriana R. Pohlmann
Summary: Chemotherapy-related cognitive impairment (CRCI) has become a focus of research in the past years due to its potential adverse effects on breast cancer patients. This review provides an overview of the molecular mechanisms linking individual drugs used in breast cancer treatment to CRCI, the clinical characteristics of CRCI in patients, and possible therapeutic interventions. The incidence rates of CRCI in breast cancer vary considerably and may affect more than 50% of treated patients. Although there is currently no standard treatment for CRCI, various pharmacological and non-pharmacological approaches have shown promising results.
Article
Oncology
Paula R. Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa Lynce, Robert Warren, Asma Dilawari, Suman Rao, Candace Mainor, Nicole Swanson, Ming Tan, Claudine Isaacs, Sandra M. Swain
Summary: The study aimed to evaluate whether crofelemer could prevent chemotherapy-induced diarrhea in HER2-positive breast cancer patients receiving specific treatment. The results demonstrated that crofelemer reduced the incidence and severity of CID.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jason A. Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbe, Harshada Joshi, Wendy Snyder, Janice M. Mehnert
Summary: In a randomized phase II study, the combination of T-VEC and ipilimumab showed greater antitumor activity compared to ipilimumab alone in patients with advanced melanoma. The 5-year outcomes demonstrated long-lasting efficacy and safety for the combination therapy of an oncolytic virus and a checkpoint inhibitor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Medicine, Research & Experimental
Tina Roy, Elizabeth Barrows, Candace Mainor, Julie Collins, Filipa Lynce, Claudine Isaacs, Paula R. Pohlmann
Summary: Standard treatment for metastatic HR+ breast cancer includes use of CDK4/6 inhibitor and antiestrogen therapy. Endocrine resistance remains a challenge, but the Src/Abl pathway shows promise as a target for novel therapies. This trial evaluates the combination of palbociclib, fulvestrant, and bosutinib in patients who have progressed on previous treatments.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
(2023)
Article
Oncology
Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P. Ikeguchi, Igor Puzanov, Susanne Arnold, Michelle Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner, Issam M. El Naqa, Ahmad A. Tarhini
Summary: In this study, the prognostic value of immunoscore calculated from real-world transcriptomic data was evaluated in patients with advanced malignancies treated with immune checkpoint inhibitors. The results demonstrated that the immunoscore could predict patients at risk of death, with better overall survival observed in patients with intermediate-high immunoscore.
Article
Oncology
Lei Deng, Changchuan Jiang, Kristopher Attwood, Joseph J. Zhao, Stuthi Perimbeti, Chen Hu, Igor Puzanov, Grace K. Dy
Summary: Durable progression-free survivors (dPFSors) over 2 years have been reported among patients with melanoma or non-small-cell lung cancer (NSCLC) who received PD-(L)1 therapy. However, risk of progression still exists and the optimal imaging surveillance interval is unknown.
JCO ONCOLOGY PRACTICE
(2023)
Meeting Abstract
Oncology
Latha Shivakumar, Christine B. Weldon, Ali McBride, Igor Puzanov, Joanne Riemer, Matthew R. Zibelman, Leigh Boehmer
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Medicine, Research & Experimental
Adi Diab, Igor Puzanov, Michele Maio, Brendan Curti, Mehmet Bilen, Karl Lewis, Scott Tykodi, Gregory Daniels, Alexander Spira, Chantale Bernatchez, Salah Eddine Bentebibel, Michael Wong, James Larkin, Ewa Kalinka-Warzocha, Sunny Xie, Sue Currie, Ute Hoch, Wei Lin, Mary Tagliaferri, Stina Singel, Michael Hurwitz
JOURNAL OF TRANSLATIONAL MEDICINE
(2020)
